{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"146-366-063-361-972","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"146-366-063-361-972"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8676,"type":"PATENT","title":"New York University Patent Portforlio ","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5145,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2015-11-12T00:15:20Z","updated":"2015-11-23T01:36:42Z","lastEventDate":"2015-11-23T01:36:42Z"},{"id":8877,"type":"PATENT","title":"New York Univ Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15466,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8211,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners seperately = \"New York Univ\", \"New York University NOT \"state\" NOT \"city\" \", \"Univ New York\", \"NYU\".
Search Applicants and Owners seperately = \"New York Univ\", \"New York University NOT \"state\" NOT \"city\" \", \"Univ New York\", \"NYU\".
the avirulent, oncolytic modified herpes simplex virus according to claim 1, and a pharmaceutically acceptable vehicle for in situ administration to tumor cells."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition according to claim 7, wherein the wild-type herpes simplex virus is herpes simplex virus type 1."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A method for killing tumor cells in a subject comprising:\n
administering to a subject the avirulent, oncolytic modified herpes simplex virus according to claim 1 under conditions effective to kill tumor cells in the subject."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 9, wherein the tumor cells are selected from the group consisting of astrocytoma, oligodendroglioma, meningioma, neurofibroma, glioblastoma, ependymoma, Schwannoma, neurofibrosarcoma, medulloblastoma, melanoma cells, pancreatic cancer cells, prostate carcinoma cells, breast cancer cells, lung cancer cells, colon cancer cells, lymphoma cells, hepatoma cells, mesothelioma and epidermoid carcinoma cells."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 9, wherein the administering is carried out by injection, infusion, instillation or inhalation."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 9, wherein the subject is a mammal."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 12, wherein the mammal is a human."],"number":13,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}